
	Search		Keep Me Updated		Tell a Friend		Add to My Favorites

PRELIMINARY SCIENTIFIC PROGRAM

Section: Retina Diseases
Chairpersons: B.D. Kuppermann, USA J. Cunha-Vaz, Portugal
Treatment for CNV	Back To Section List
Characterization of AMD Subtypes Needed for Choice of Therapy R. Silva, Portugal
Lucentis for CNV in AMD G. Staurenghi, Italy
Avastin for CNV in AMD S. Michels, Austria
Macugen for CNV in AMD M. Tolentino, USA
Low Dose Systemic Avastin B.D. Kuppermann, USA
Full Thickness Avastin Penetrance U. Schraermeyer, Germany
Lucentis for Non-AMD CNV J. Mones, Spain

Research and Development for CNV in AMD	Back To Section List
Small Molecule Integrin Inhibitor J.S. Heier, USA
RTP 801 Inhibition siRNA J. Ambati, USA
The VEGF Trap Q.D. Nguyen, USA
siRNA P. Kaiser, USA
Α5Β1 INTEGRIN ANTAGONISM IN AMD: A MONOCLONAL ANTIBODY APPROACH WITH VOLOCIXIMAB S. Patel, USA
Intraocular Delivery Of Pegaptanib Sodium With Sustained Release Microspheres M. Tolentino, USA
TargeGen 801 Topical Therapy R.M. Soll, USA
Novel Topical Anti-Angiogenic Therapies for Neovascular Ocular Diseases M. (K.) Kengatharan, USA
Topical Anti-angiogenic and Angiolytic Therapy for AMD C.M. Greven, USA
Approaches to Managing CNV: Looking Beyond VEGF Pathway Q.D. Nguyen, USA
Complement Activation Leading to CNV in AMD J. Ambati, USA
Rapamycin and Related MTOR Inhibitors for CNV in AMD A. Laties, USA

Dry AMD	Back To Section List
Genistein for AMD E. deJuan, USA
Othera Topical Therapy for Atrophic AMD D. Boyer, USA
Complement Inhibition for Dry AMD C. Francois, USA
Retinoids for AMD E. deJuan, USA
Nutritional Therapy for AMD M.J. Cooney, USA
CNTF for Retinal Degenerations and Atrophic AMD W. Tao, USA
Fenretinide for Geographic Atrophy R. Vogel, USA

Macular Edema	Back To Section List
Lucentis for Vein Occlusion P. Campochiaro, USA
Avastin for Macular Edema due to RVO D. Do, USA
Macugen for Macular Edema Secondary to CRVO: Results of a Phase 2 Randomized Clinical Trial A. Loewenstein, Israel
Triamcinolone for Vein Occlusion J. Jonas, Germany
Retisert FA Implant Uveitis M. Zierhut, Germany
Posurdex for Persistent Macular Edema B.D. Kuppermann, USA

Diabetic Macular Edema	Back To Section List
Clinical Characterization & Management Strategies J. Cunha-Vaz, Portugal
Lucentis in DME D. Do, USA
Avastin for DME A. Loewenstein, Israel
Treatment of Diabetic Macular Edema (DME) with Pegaptanib (Macugen) - Two Year Follow-up E. Ergun, Austria
Triamcinolone for DME J. Jonas, Germany
The Helical Coil Drug Technology for DME E. deJuan, USA
TA Microspheres for DME J.A. Cardillo, Brazil
Medidur FA Implant J. Figueira, Portugal
Retisert FA implant D. Eliott, USA
Dexamethasone Lipid Emulsion for DME G. Lambert, France
Micropulse Laser V. Chong, UK

Diabetic Retinopathy	Back To Section List
Vitrase for Vitreous Hemorrhage and NPDR B.D. Kuppermann, USA
Octreotide for Diabetic Retinopathy D. Boyer, USA
Avastin for PDR J. Mones, Spain
iCo-007, a VEGF "+" Agent for the Potential Treatment of Diabetic Macular Edema and Diabetic Retinopathy P. Hnik, Canada

Vitreolytics - PVR - Retinal Neovascularisation	Back To Section List
MicroPlasmin M.D. de Smet, The Netherlands
Vitreosolve as a Surgical Adjuvant for Vitrectomy BD Kuppermann, USA
Retinal Neuroprotection J. Burke, USA
Anti-angiogenic Therapy for ROP K. Drenser, USA

Combination Drug - Laser - Surgical Approaches	Back To Section List
Combination PDT for CNV in AMD - VERITAS Trial P. Kaiser, USA
Triple Combination Therapy for CNV in AMD A. Augustin, Germany
Combination Brachytherapy and anti-VEGF therapy for CNV in AMD J.S. Heier, USA
Combination Therapy for Diabetic Macula Edema A. Augustin, USA

Site Map